CMS Finalizes Mandatory GLOBE Model to Lower Part B Drug Prices

New international pricing benchmark will test lower rebate-based costs for roughly 25% of Original Medicare beneficiaries

The Centers for Medicare & Medicaid Services (CMS) has finalized the Global Benchmark for Efficient Drug Pricing (GLOBE) Model, a new mandatory payment model aimed at cutting drug costs in Original Medicare Part B while protecting quality of care.
“Medicare Part B patients and American taxpayers have paid significantly more for prescription medications than people in comparable countries,” said CMS Administrator Dr. Mehmet Oz. “At CMS, we’re focused on more than promises to make healthcare more affordable. We’re taking action to pilot a new approach to lower costs and strengthen the quality of care while preserving medical innovation.”

Why CMS Is Acting

The numbers behind the model are hard to ignore. Americans pay more than four times as much for brand-name prescription drugs as people in other developed countries. HHS data also shows Part B drug spending grew nearly four times as fast as drug spending across all payers between 2008 and 2021. HHS ASPE

How GLOBE Works

GLOBE changes how Part B drug inflation rebates are calculated for certain separately payable drugs and biologicals, the medications clinicians typically administer in healthcare settings. Instead of the current approach, the model uses international pricing data to set a benchmark based on prices paid in a group of economically comparable countries.
Several categories are excluded. Biosimilars and their reference biologicals are out once a biosimilar enters the U.S. market. Orphan-only drugs, plasma-derived products, and certain cell and gene therapies are also excluded, a change from the proposed rule made in response to public comments.

Timeline and Scope

  • The model runs for five years, from January 1, 2027 through March 31, 2032.
  • Manufacturer rebate invoicing and reconciliation continues until March 31, 2034.
  • It applies to beneficiaries in a randomly selected set of geographic areas, covering about 25% of beneficiaries with Original Medicare as their primary coverage.
  • Affected beneficiaries may see lower out-of-pocket costs starting April 1, 2027. CMS GLOBE Model
CMS Finalizes Mandatory GLOBE Model to Lower Part B Drug Prices

What This Means for Healthcare Organizations

GLOBE puts manufacturer rebates, not provider payment rates, at the center of the model. Still, providers who administer Part B drugs in selected regions should prepare for change. Coinsurance for affected drugs could drop for patients, which may shift collection patterns and patient balances. Practice and revenue cycle teams should identify which of their locations fall inside selected geographic areas and flag high-volume Part B drugs that could be covered. Watch for CMS guidance on region selection and the list of included drugs as the January 2027 start approaches.
CMS-What-This-Means-for-Healthcare-Organizations